The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.

The newly approved drug-device combination helps patients manage their own treatment from the comfort of home. 

The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others.

New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.

If familial hypercholesterolemia is not detected and treated early, it can lead to premature heart attacks and heart disease in young patients.

The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote. 

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Evinacumab-dgnb, sold by Regeneron under the brand name Evkeeza, can now be used to treat homozygous familial hypercholesterolemia in much younger patients.